Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients-Reference-Cited by-同舟云学术

Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients

Published:2024-03-26 Issue:11 Volume:130 Page:1866-1874
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Puszkiel Alicja^ORCID,Bianconi Guillaume,Pasquiers Blaise^ORCID,Balakirouchenane David,Arrondeau Jennifer,Boudou-Rouquette Pascaline,Bretagne Marie-Claire,Salem Joe-Elie,Declèves Xavier,Vidal Michel,Kramkimel Nora,Guegan Sarah,Aractingi Selim,Huillard Olivier^ORCID,Alexandre Jérôme^ORCID,Wislez Marie,Goldwasser François,Blanchet Benoit

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41416-024-02659-x.pdf

Reference41 articles.

1. Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19:254–67.

2. Desnoyer A, Broutin S, Delahousse J, Maritaz C, Blondel L, Mir O, et al. Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies. Eur J Cancer. 2020;128:119–28.

3. Yu PP, Eton O, Garrison LP. Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer. J Immunother Cancer. 2019;7:235.

4. Wesevich A, Goldstein DA, Paydary K, Peer CJ, Figg WD, Ratain MJ. Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies. Br J Cancer. 2023;1–8.

5. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167–75.